A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

The startup is bringing into Phase 1 testing an experimental treatment it says could be more effective than marketed ...

The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development ...

The DNA-testing company plans to sell its assets after the board rejected an acquisition proposal from Wojcicki.

The company expects next quarter to read out initial data from its Heart-2 trial, which is testing a one-time treatment for people with genetically elevated cholesterol.

This was seen recently in January 2025, when GSK (LSE/NYSE: GSK) acquired IDRx, a Boston-based biotech specializing in precision therapies for gastrointestinal stromal tumors (GIST). Initially, GSK ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...

A panel of CDC advisers, who had originally been set to meet in February, will discuss the current measles outbreak as well ...